1 Neurofibromatoses Type II Therapecutics Market Overview 1.1 Neurofibromatoses Type II Therapecutics Product Scope 1.2 Neurofibromatoses Type II Therapecutics Segment by Type 1.2.1 Global Neurofibromatoses Type II Therapecutics Sales by Type (2016 & 2021 & 2027) 1.2.2 AR-42 1.2.3 FRAX-597 1.2.4 Icotinib Hydrochloride 1.2.5 LB-201 1.2.6 LB-205 1.2.7 Others 1.3 Neurofibromatoses Type II Therapecutics Segment by Application 1.3.1 Global Neurofibromatoses Type II Therapecutics Sales Comparison by Application (2016 & 2021 & 2027) 1.3.2 Clinic 1.3.3 Hospital 1.3.4 Home Care 1.4 Neurofibromatoses Type II Therapecutics Market Estimates and Forecasts (2016-2027) 1.4.1 Global Neurofibromatoses Type II Therapecutics Market Size in Value Growth Rate (2016-2027) 1.4.2 Global Neurofibromatoses Type II Therapecutics Market Size in Volume Growth Rate (2016-2027) 1.4.3 Global Neurofibromatoses Type II Therapecutics Price Trends (2016-2027) 2 Neurofibromatoses Type II Therapecutics Estimates and Forecasts by Region 2.1 Global Neurofibromatoses Type II Therapecutics Market Size by Region: 2016 VS 2021 VS 2027 2.2 Global Neurofibromatoses Type II Therapecutics Retrospective Market Scenario by Region (2016-2021) 2.2.1 Global Neurofibromatoses Type II Therapecutics Sales Market Share by Region (2016-2021) 2.2.2 Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region (2016-2021) 2.3 Global Neurofibromatoses Type II Therapecutics Market Estimates and Forecasts by Region (2022-2027) 2.3.1 Global Neurofibromatoses Type II Therapecutics Sales Estimates and Forecasts by Region (2022-2027) 2.3.2 Global Neurofibromatoses Type II Therapecutics Revenue Forecast by Region (2022-2027) 2.4 Geographic Market Analysis: Market Facts & Figures 2.4.1 North America Neurofibromatoses Type II Therapecutics Estimates and Projections (2016-2027) 2.4.2 Europe Neurofibromatoses Type II Therapecutics Estimates and Projections (2016-2027) 2.4.3 China Neurofibromatoses Type II Therapecutics Estimates and Projections (2016-2027) 2.4.4 Japan Neurofibromatoses Type II Therapecutics Estimates and Projections (2016-2027) 2.4.5 Southeast Asia Neurofibromatoses Type II Therapecutics Estimates and Projections (2016-2027) 2.4.6 India Neurofibromatoses Type II Therapecutics Estimates and Projections (2016-2027) 3 Global Neurofibromatoses Type II Therapecutics Competition Landscape by Players 3.1 Global Top Neurofibromatoses Type II Therapecutics Players by Sales (2016-2021) 3.2 Global Top Neurofibromatoses Type II Therapecutics Players by Revenue (2016-2021) 3.3 Global Neurofibromatoses Type II Therapecutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurofibromatoses Type II Therapecutics as of 2020) 3.4 Global Neurofibromatoses Type II Therapecutics Average Price by Company (2016-2021) 3.5 Manufacturers Neurofibromatoses Type II Therapecutics Manufacturing Sites, Area Served, Product Type 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Global Neurofibromatoses Type II Therapecutics Market Size by Type 4.1 Global Neurofibromatoses Type II Therapecutics Historic Market Review by Type (2016-2021) 4.1.1 Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2021) 4.1.2 Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Type (2016-2021) 4.1.3 Global Neurofibromatoses Type II Therapecutics Price by Type (2016-2021) 4.2 Global Neurofibromatoses Type II Therapecutics Market Estimates and Forecasts by Type (2022-2027) 4.2.1 Global Neurofibromatoses Type II Therapecutics Sales Forecast by Type (2022-2027) 4.2.2 Global Neurofibromatoses Type II Therapecutics Revenue Forecast by Type (2022-2027) 4.2.3 Global Neurofibromatoses Type II Therapecutics Price Forecast by Type (2022-2027) 5 Global Neurofibromatoses Type II Therapecutics Market Size by Application 5.1 Global Neurofibromatoses Type II Therapecutics Historic Market Review by Application (2016-2021) 5.1.1 Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2021) 5.1.2 Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Application (2016-2021) 5.1.3 Global Neurofibromatoses Type II Therapecutics Price by Application (2016-2021) 5.2 Global Neurofibromatoses Type II Therapecutics Market Estimates and Forecasts by Application (2022-2027) 5.2.1 Global Neurofibromatoses Type II Therapecutics Sales Forecast by Application (2022-2027) 5.2.2 Global Neurofibromatoses Type II Therapecutics Revenue Forecast by Application (2022-2027) 5.2.3 Global Neurofibromatoses Type II Therapecutics Price Forecast by Application (2022-2027) 6 North America Neurofibromatoses Type II Therapecutics Market Facts & Figures 6.1 North America Neurofibromatoses Type II Therapecutics Sales by Company 6.1.1 North America Neurofibromatoses Type II Therapecutics Sales by Company (2016-2021) 6.1.2 North America Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) 6.2 North America Neurofibromatoses Type II Therapecutics Sales Breakdown by Type 6.2.1 North America Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2016-2021) 6.2.2 North America Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2022-2027) 6.3 North America Neurofibromatoses Type II Therapecutics Sales Breakdown by Application 6.3.1 North America Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2016-2021) 6.3.2 North America Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2022-2027) 7 Europe Neurofibromatoses Type II Therapecutics Market Facts & Figures 7.1 Europe Neurofibromatoses Type II Therapecutics Sales by Company 7.1.1 Europe Neurofibromatoses Type II Therapecutics Sales by Company (2016-2021) 7.1.2 Europe Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) 7.2 Europe Neurofibromatoses Type II Therapecutics Sales Breakdown by Type 7.2.1 Europe Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2016-2021) 7.2.2 Europe Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2022-2027) 7.3 Europe Neurofibromatoses Type II Therapecutics Sales Breakdown by Application 7.3.1 Europe 122 Sales Breakdown by Application (2016-2021) 7.3.2 Europe 122 Sales Breakdown by Application (2022-2027) 8 China Neurofibromatoses Type II Therapecutics Market Facts & Figures 8.1 China Neurofibromatoses Type II Therapecutics Sales by Company 8.1.1 China Neurofibromatoses Type II Therapecutics Sales by Company (2016-2021) 8.1.2 China Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) 8.2 China Neurofibromatoses Type II Therapecutics Sales Breakdown by Type 8.2.1 China Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2016-2021) 8.2.2 China Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2022-2027) 8.3 China Neurofibromatoses Type II Therapecutics Sales Breakdown by Application 8.3.1 China 144 Sales Breakdown by Application (2016-2021) 8.3.2 China 144 Sales Breakdown by Application (2022-2027) 9 Japan Neurofibromatoses Type II Therapecutics Market Facts & Figures 9.1 Japan Neurofibromatoses Type II Therapecutics Sales by Company 9.1.1 Japan Neurofibromatoses Type II Therapecutics Sales by Company (2016-2021) 9.1.2 Japan Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) 9.2 Japan Neurofibromatoses Type II Therapecutics Sales Breakdown by Type 9.2.1 Japan Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2016-2021) 9.2.2 Japan Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2022-2027) 9.3 Japan Neurofibromatoses Type II Therapecutics Sales Breakdown by Application 9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021) 9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027) 10 Southeast Asia Neurofibromatoses Type II Therapecutics Market Facts & Figures 10.1 Southeast Asia Neurofibromatoses Type II Therapecutics Sales by Company 10.1.1 Southeast Asia Neurofibromatoses Type II Therapecutics Sales by Company (2016-2021) 10.1.2 Southeast Asia Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) 10.2 Southeast Asia Neurofibromatoses Type II Therapecutics Sales Breakdown by Type 10.2.1 Southeast Asia Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2016-2021) 10.2.2 Southeast Asia Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2022-2027) 10.3 Southeast Asia Neurofibromatoses Type II Therapecutics Sales Breakdown by Application 10.3.1 Southeast Asia K Pcs Sales Breakdown by Application (2016-2021) 10.3.2 Southeast Asia K Pcs Sales Breakdown by Application (2022-2027) 11 India Neurofibromatoses Type II Therapecutics Market Facts & Figures 11.1 India Neurofibromatoses Type II Therapecutics Sales by Company 11.1.1 India Neurofibromatoses Type II Therapecutics Sales by Company (2016-2021) 11.1.2 India Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) 11.2 India Neurofibromatoses Type II Therapecutics Sales Breakdown by Type 11.2.1 India Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2016-2021) 11.2.2 India Neurofibromatoses Type II Therapecutics Sales Breakdown by Type (2022-2027) 11.3 India Neurofibromatoses Type II Therapecutics Sales Breakdown by Application 11.3.1 India Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2016-2021) 11.3.2 India Neurofibromatoses Type II Therapecutics Sales Breakdown by Application (2022-2027) 12 Company Profiles and Key Figures in Neurofibromatoses Type II Therapecutics Business 12.1 Arno Therapeutics Inc 12.1.1 Arno Therapeutics Inc Corporation Information 12.1.2 Arno Therapeutics Inc Business Overview 12.1.3 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2016-2021) 12.1.4 Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Products Offered 12.1.5 Arno Therapeutics Inc Recent Development 12.2 AstraZeneca Plc 12.2.1 AstraZeneca Plc Corporation Information 12.2.2 AstraZeneca Plc Business Overview 12.2.3 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2016-2021) 12.2.4 AstraZeneca Plc Neurofibromatoses Type II Therapecutics Products Offered 12.2.5 AstraZeneca Plc Recent Development 12.3 Beta Pharma Inc 12.3.1 Beta Pharma Inc Corporation Information 12.3.2 Beta Pharma Inc Business Overview 12.3.3 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2016-2021) 12.3.4 Beta Pharma Inc Neurofibromatoses Type II Therapecutics Products Offered 12.3.5 Beta Pharma Inc Recent Development 12.4 Lixte Biotechnology Holdings Inc 12.4.1 Lixte Biotechnology Holdings Inc Corporation Information 12.4.2 Lixte Biotechnology Holdings Inc Business Overview 12.4.3 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2016-2021) 12.4.4 Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Products Offered 12.4.5 Lixte Biotechnology Holdings Inc Recent Development 12.5 Plex Pharmaceuticals Inc 12.5.1 Plex Pharmaceuticals Inc Corporation Information 12.5.2 Plex Pharmaceuticals Inc Business Overview 12.5.3 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2016-2021) 12.5.4 Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Products Offered 12.5.5 Plex Pharmaceuticals Inc Recent Development 12.6 Recursion Pharmaceuticals Inc 12.6.1 Recursion Pharmaceuticals Inc Corporation Information 12.6.2 Recursion Pharmaceuticals Inc Business Overview 12.6.3 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales, Revenue and Gross Margin (2016-2021) 12.6.4 Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Products Offered 12.6.5 Recursion Pharmaceuticals Inc Recent Development ... 13 Neurofibromatoses Type II Therapecutics Manufacturing Cost Analysis 13.1 Neurofibromatoses Type II Therapecutics Key Raw Materials Analysis 13.1.1 Key Raw Materials 13.1.2 Key Raw Materials Price Trend 13.1.3 Key Suppliers of Raw Materials 13.2 Proportion of Manufacturing Cost Structure 13.3 Manufacturing Process Analysis of Neurofibromatoses Type II Therapecutics 13.4 Neurofibromatoses Type II Therapecutics Industrial Chain Analysis 14 Marketing Channel, Distributors and Customers 14.1 Marketing Channel 14.2 Neurofibromatoses Type II Therapecutics Distributors List 14.3 Neurofibromatoses Type II Therapecutics Customers 15 Market Dynamics 15.1 Neurofibromatoses Type II Therapecutics Market Trends 15.2 Neurofibromatoses Type II Therapecutics Drivers 15.3 Neurofibromatoses Type II Therapecutics Market Challenges 15.4 Neurofibromatoses Type II Therapecutics Market Restraints 16 Research Findings and Conclusion 17 Appendix 17.1 Research Methodology 17.1.1 Methodology/Research Approach 17.1.2 Data Source 17.2 Author List 17.3 Disclaimer

List of Tables Table 1. Global Neurofibromatoses Type II Therapecutics Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027) Table 2. Global Neurofibromatoses Type II Therapecutics Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027) Table 3. Global Neurofibromatoses Type II Therapecutics Market Size (US$ Million) by Region: 2016 VS 2021 &2027 Table 4. Global Neurofibromatoses Type II Therapecutics Sales (K Pcs) by Region (2016-2021) Table 5. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Region (2016-2021) Table 6. Global Neurofibromatoses Type II Therapecutics Revenue (US$ Million) Market Share by Region (2016-2021)) Table 7. Global Neurofibromatoses Type II Therapecutics Revenue Share by Region (2016-2021) Table 8. Global Neurofibromatoses Type II Therapecutics Sales (K Pcs) Forecast by Region (2022-2027) Table 9. Global Neurofibromatoses Type II Therapecutics Sales Market Share Forecast by Region (2022-2027) Table 10. Global Neurofibromatoses Type II Therapecutics Revenue (US$ Million) Forecast by Region (2022-2027) Table 11. Global Neurofibromatoses Type II Therapecutics Revenue Share Forecast by Region (2022-2027) Table 12. Global Neurofibromatoses Type II Therapecutics Sales (K Pcs) of Key Companies (2016-2021) Table 13. Global Neurofibromatoses Type II Therapecutics Sales Share by Company (2016-2021) Table 14. Global Neurofibromatoses Type II Therapecutics Revenue (US$ Million) by Company (2016-2021) Table 15. Global Neurofibromatoses Type II Therapecutics Revenue Share by Company (2016-2021) Table 16. Global Neurofibromatoses Type II Therapecutics by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurofibromatoses Type II Therapecutics as of 2020) Table 17. Global Neurofibromatoses Type II Therapecutics Average Price (USD/Pcs) of Key Company (2016-2021) Table 18. Manufacturers Neurofibromatoses Type II Therapecutics Manufacturing Sites and Area Served Table 19. Manufacturers Neurofibromatoses Type II Therapecutics Product Type Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans Table 21. Global Neurofibromatoses Type II Therapecutics Sales (K Pcs) by Type (2016-2021) Table 22. Global Neurofibromatoses Type II Therapecutics Sales Share by Type (2016-2021) Table 23. Global Neurofibromatoses Type II Therapecutics Revenue (US$ Million) Market Share by Type (2016-2021) Table 24. Global Neurofibromatoses Type II Therapecutics Price (USD/Pcs) by Type (2016-2021) Table 25. Global Neurofibromatoses Type II Therapecutics Sales Share by Type (2022-2027) Table 26. Global Neurofibromatoses Type II Therapecutics Revenue (US$ Million) Market Share by Type (2022-2027) Table 27. Global Neurofibromatoses Type II Therapecutics Revenue Share by Type (2022-2027) Table 28. Global Neurofibromatoses Type II Therapecutics Price (USD/Pcs) by Type (2022-2027) Table 29. Global Neurofibromatoses Type II Therapecutics Sales (K Pcs) by Application (2016-2021) Table 30. Global Neurofibromatoses Type II Therapecutics Sales Share by Application (2016-2021) Table 31. Global Neurofibromatoses Type II Therapecutics Revenue (US$ Million) Market Share by Application (2016-2021) Table 32. Global Neurofibromatoses Type II Therapecutics Price (USD/Pcs) by Application (2016-2021) Table 33. Global Neurofibromatoses Type II Therapecutics Sales (K Pcs) by Application (2022-2027) Table 34. Global Neurofibromatoses Type II Therapecutics Sales Share by Application (2022-2027) Table 35. Global Neurofibromatoses Type II Therapecutics Revenue (US$ Million) Market Share by Application (2022-2027) Table 36. Global Neurofibromatoses Type II Therapecutics Revenue Share by Application (2022-2027) Table 37. Global Neurofibromatoses Type II Therapecutics Price (USD/Pcs) by Application (2022-2027) Table 38. North America Neurofibromatoses Type II Therapecutics Sales (K Pcs) by Company (2016-2021) Table 39. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Company (2016-2021) Table 40. North America Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) & (US$ Million) Table 41. North America Neurofibromatoses Type II Therapecutics Revenue Market Share by Company (2016-2021) Table 42. North America Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 43. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2021) Table 44. North America Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 45. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2022-2027) Table 46. North America Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 47. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2021) Table 48. North America Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 49. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2022-2027) Table 50. Europe Neurofibromatoses Type II Therapecutics Sales (K Pcs) by Company (2016-2021) Table 51. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Company (2016-2021) Table 52. Europe Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) & (US$ Million) Table 53. Europe Neurofibromatoses Type II Therapecutics Revenue Market Share by Company (2016-2021) Table 54. Europe Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 55. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2021) Table 56. Europe Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 57. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2022-2027) Table 58. Europe Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 59. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2021) Table 60. Europe Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 61. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2022-2027) Table 62. China Neurofibromatoses Type II Therapecutics Sales (K Pcs) by Company (2016-2021) Table 63. China Neurofibromatoses Type II Therapecutics Sales Market Share by Company (2016-2021) Table 64. China Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) & (US$ Million) Table 65. China Neurofibromatoses Type II Therapecutics Revenue Market Share by Company (2016-2021) Table 66. China Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 67. China Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2021) Table 68. China Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 69. China Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2022-2027) Table 70. China Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 71. China Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2021) Table 72. China Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 73. China Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2022-2027) Table 74. Japan Neurofibromatoses Type II Therapecutics Sales (K Pcs) by Company (2016-2021) Table 75. Japan Neurofibromatoses Type II Therapecutics Sales Market Share by Company (2016-2021) Table 76. Japan Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) & (US$ Million) Table 77. Japan Neurofibromatoses Type II Therapecutics Revenue Market Share by Company (2016-2021) Table 78. Japan Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 79. Japan Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2021) Table 80. Japan Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 81. Japan Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2022-2027) Table 82. Japan Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 83. Japan Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2021) Table 84. Japan Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 85. Japan Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2022-2027) Table 86. Southeast Asia Neurofibromatoses Type II Therapecutics Sales (K Pcs) by Company (2016-2021) Table 87. Southeast Asia Neurofibromatoses Type II Therapecutics Sales Market Share by Company (2016-2021) Table 88. Southeast Asia Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) & (US$ Million) Table 89. Southeast Asia Neurofibromatoses Type II Therapecutics Revenue Market Share by Company (2016-2021) Table 90. Southeast Asia Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 91. Southeast Asia Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2021) Table 92. Southeast Asia Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 93. Southeast Asia Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2022-2027) Table 94. Southeast Asia Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 95. Southeast Asia Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2021) Table 96. Southeast Asia Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 97. Southeast Asia Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2022-2027) Table 98. India Neurofibromatoses Type II Therapecutics Sales (K Pcs) by Company (2016-2021) Table 99. India Neurofibromatoses Type II Therapecutics Sales Market Share by Company (2016-2021) Table 100. India Neurofibromatoses Type II Therapecutics Revenue by Company (2016-2021) & (US$ Million) Table 101. India Neurofibromatoses Type II Therapecutics Revenue Market Share by Company (2016-2021) Table 102. India Neurofibromatoses Type II Therapecutics Sales by Type (2016-2021) & (K Pcs) Table 103. India Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2016-2021) Table 104. India Neurofibromatoses Type II Therapecutics Sales by Type (2022-2027) & (K Pcs) Table 105. India Neurofibromatoses Type II Therapecutics Sales Market Share by Type (2022-2027) Table 106. India Neurofibromatoses Type II Therapecutics Sales by Application (2016-2021) & (K Pcs) Table 107. India Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2016-2021) Table 108. India Neurofibromatoses Type II Therapecutics Sales by Application (2022-2027) & (K Pcs) Table 109. India Neurofibromatoses Type II Therapecutics Sales Market Share by Application (2022-2027) Table 110. Arno Therapeutics Inc Corporation Information Table 111. Arno Therapeutics Inc Description and Business Overview Table 112. Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 113. Arno Therapeutics Inc Neurofibromatoses Type II Therapecutics Product Table 114. Arno Therapeutics Inc Recent Development Table 115. AstraZeneca Plc Corporation Information Table 116. AstraZeneca Plc Description and Business Overview Table 117. AstraZeneca Plc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 118. AstraZeneca Plc Neurofibromatoses Type II Therapecutics Product Table 119. AstraZeneca Plc Recent Development Table 120. Beta Pharma Inc Corporation Information Table 121. Beta Pharma Inc Description and Business Overview Table 122. Beta Pharma Inc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 123. Beta Pharma Inc Neurofibromatoses Type II Therapecutics Product Table 124. Beta Pharma Inc Recent Development Table 125. Lixte Biotechnology Holdings Inc Corporation Information Table 126. Lixte Biotechnology Holdings Inc Description and Business Overview Table 127. Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 128. Lixte Biotechnology Holdings Inc Neurofibromatoses Type II Therapecutics Product Table 129. Lixte Biotechnology Holdings Inc Recent Development Table 130. Plex Pharmaceuticals Inc Corporation Information Table 131. Plex Pharmaceuticals Inc Description and Business Overview Table 132. Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 133. Plex Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Table 134. Plex Pharmaceuticals Inc Recent Development Table 135. Recursion Pharmaceuticals Inc Corporation Information Table 136. Recursion Pharmaceuticals Inc Description and Business Overview Table 137. Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021) Table 138. Recursion Pharmaceuticals Inc Neurofibromatoses Type II Therapecutics Product Table 139. Recursion Pharmaceuticals Inc Recent Development Table 140. Production Base and Market Concentration Rate of Raw Material Table 141. Key Suppliers of Raw Materials Table 142. Neurofibromatoses Type II Therapecutics Distributors List Table 143. Neurofibromatoses Type II Therapecutics Customers List Table 144. Neurofibromatoses Type II Therapecutics Market Trends Table 145. Neurofibromatoses Type II Therapecutics Market Drivers Table 146. Neurofibromatoses Type II Therapecutics Market Challenges Table 147. Neurofibromatoses Type II Therapecutics Market Restraints Table 148. Research Programs/Design for This Report Table 149. Key Data Information from Secondary Sources Table 150. Key Data Information from Primary Sources List of Figures Figure 1. Neurofibromatoses Type II Therapecutics Product Picture Figure 2. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Type in 2021 & 2027 Figure 3. AR-42 Product Picture Figure 4. FRAX-597 Product Picture Figure 5. Icotinib Hydrochloride Product Picture Figure 6. LB-201 Product Picture Figure 7. LB-205 Product Picture Figure 8. Others Product Picture Figure 9. Global Neurofibromatoses Type II Therapecutics Sales Market Share by Application in 2021 & 2027 Figure 10. Clinic Examples Figure 11. Hospital Examples Figure 12. Home Care Examples Figure 13. Global Neurofibromatoses Type II Therapecutics Sales, (US$ Million), 2016 VS 2021 VS 2027 Figure 14. Global Neurofibromatoses Type II Therapecutics Sales Growth Rate (2016-2027) & (US$ Million) Figure 15. Global Neurofibromatoses Type II Therapecutics Sales (K Pcs) Growth Rate (2016-2027) Figure 16. Global Neurofibromatoses Type II Therapecutics Price Trends Growth Rate (2016-2027) (USD/Pcs) Figure 17. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region: 2016 VS 2021 Figure 18. Global Neurofibromatoses Type II Therapecutics Revenue Market Share by Region: 2021 VS 2027 Figure 19. North America Neurofibromatoses Type II Therapecutics Revenue (Million USD) Growth Rate (2016-2027) Figure 20. North America Neurofibromatoses Type II Therapecutics Sales (K Pcs) Growth Rate (2016-2027) Figure 21. Europe Neurofibromatoses Type II Therapecutics Revenue (Million USD) Growth Rate (2016-2027) Figure 22. Europe Neurofibromatoses Type II Therapecutics Sales (Million USD) Growth Rate (2016-2027) Figure 23. China Neurofibromatoses Type II Therapecutics Revenue (Million USD) Growth Rate (2016-2027) Figure 24. China Neurofibromatoses Type II Therapecutics Sales (Million USD) and Growth Rate (2016-2027) Figure 25. Japan Neurofibromatoses Type II Therapecutics Revenue (Million USD) Growth Rate (2016-2027) Figure 26. Japan Neurofibromatoses Type II Therapecutics Sales (Million USD) Growth Rate (2016-2027) Figure 27. Southeast Asia Neurofibromatoses Type II Therapecutics Revenue (Million USD) Growth Rate (2016-2027) Figure 28. Southeast Asia Neurofibromatoses Type II Therapecutics Sales (Million USD) Growth Rate (2016-2027) Figure 29. India Neurofibromatoses Type II Therapecutics Revenue (Million USD) Growth Rate (2016-2027) Figure 30. India Neurofibromatoses Type II Therapecutics Sales (Million USD) Growth Rate (2016-2027) Figure 31. Global 5 Largest Neurofibromatoses Type II Therapecutics Players Market Share by Revenue in Neurofibromatoses Type II Therapecutics: 2016 & 2020 Figure 32. Neurofibromatoses Type II Therapecutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 33. Global Neurofibromatoses Type II Therapecutics Revenue Share by Type (2016-2021) Figure 34. Global Neurofibromatoses Type II Therapecutics Revenue Growth Rate by Type in 2016 & 2020 Figure 35. Global Neurofibromatoses Type II Therapecutics Revenue Share by Application (2016-2021) Figure 36. Global Neurofibromatoses Type II Therapecutics Revenue Growth Rate by Application in 2016 & 2020 Figure 37. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Type in 2020 Figure 38. North America Neurofibromatoses Type II Therapecutics Sales Market Share by Application in 2020 Figure 39. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Type in 2020 Figure 40. Europe Neurofibromatoses Type II Therapecutics Sales Market Share by Application in 2020 Figure 41. China Neurofibromatoses Type II Therapecutics Sales Market Share by Type in 2020 Figure 42. China Neurofibromatoses Type II Therapecutics Sales Market Share by Application in 2020 Figure 43. Japan Neurofibromatoses Type II Therapecutics Sales Market Share by Type in 2020 Figure 44. Japan Neurofibromatoses Type II Therapecutics Sales Market Share by Application in 2020 Figure 45. Southeast Asia Neurofibromatoses Type II Therapecutics Sales Market Share by Type in 2020 Figure 46. Southeast Asia Neurofibromatoses Type II Therapecutics Sales Market Share by Application in 2020 Figure 47. India Neurofibromatoses Type II Therapecutics Sales Market Share by Type in 2020 Figure 48. India Neurofibromatoses Type II Therapecutics Sales Market Share by Application in 2020 Figure 49. Key Raw Materials Price Trend Figure 50. Manufacturing Cost Structure of Neurofibromatoses Type II Therapecutics Figure 51. Manufacturing Process Analysis of Neurofibromatoses Type II Therapecutics Figure 52. Neurofibromatoses Type II Therapecutics Industrial Chain Analysis Figure 53. Channels of Distribution Figure 54. Distributors Profiles Figure 55. Bottom-up and Top-down Approaches for This Report Figure 56. Data Triangulation Figure 57. Key Executives Interviewed

Arno Therapeutics Inc AstraZeneca Plc Beta Pharma Inc Lixte Biotechnology Holdings Inc Plex Pharmaceuticals Inc Recursion Pharmaceuticals Inc